Skip to main content

Duopa FDA Approval History

FDA Approved: Yes (First approved January 12, 2015)
Brand name: Duopa
Generic name: carbidopa and levodopa
Dosage form: Enteral Suspension
Company: AbbVie Inc.
Treatment for: Parkinson's Disease

Duopa (carbidopa and levodopa) is an aromatic amino acid decarboxylation inhibitor and aromatic amino acid combination formulated as an enteral suspension for the treatment of motor fluctuations in patients with advanced Parkinson’s disease.

Development timeline for Duopa

Oct 19, 2022BioVie’s Phase 2 Trial Assessing NE3107's Pro-motoric Activity in Parkinson's Disease is Fully Enrolled
Jan 12, 2015Approval FDA Approves Duopa (carbidopa and levodopa) Enteral Suspension for Parkinson's Disease

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.